Vasogenic shock physiology

Open Access Emergency Medicine

Volumn 3, Issue , 2011, Pages 1-6

  Gkisioti, Sotiria ^a   Mentzelopoulos, Spyros D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

H2S; KATP channels; Nitric oxide synthases; Vasoplegic syndrome; Vasopressin

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CATECHOLAMINE; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; HYDROGEN SULFIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; VASOPRESSIN;

BLOOD PRESSURE REGULATION; CALCIUM MOBILIZATION; CAUSAL ATTRIBUTION; DOSE RESPONSE; FLUID RESUSCITATION; HUMAN; LOW DRUG DOSE; MEDIATOR RELEASE; MICROCIRCULATION; MOLECULAR PATHOLOGY; NONHUMAN; ORGAN BLOOD FLOW; OXYGEN SUPPLY; REVIEW; SEPTIC SHOCK; SHOCK; VASODILATATION; VASOGENIC SHOCK;

EID: 79952790892     PISSN: None     EISSN: 11791500     Source Type: Journal    
DOI: 10.2147/OAEM.S10388     Document Type: Review

References (57)

1. Weil MH, Shubin H. Proposed reclassification of shock states with special reference to distributive defects. Adv Exp Med Biol. 1971;23: 13-23.
2. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588-595.
3. Romberg E, Pässler H, Bruhns C, Müller W. Untersuchungen über die allgemeine Pathologie and Therapie der Kreislaufstörung bie acuten Infectionskrankheiten. Arch Klin Med. 1899;64:652-714.
4. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420: 885-891.
5. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endotheliumderived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265-9269.
6. Hauser B, Bracht H, Matejovic M, Radermacher P, Venkatesh B. Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies. Anesth Analg. 2005;101:488-498.
7. Chandra A, Enkhbaatar P, Nakano Y, Traber LD, Traber DL. Sepsis: emerging role of nitric oxide and selectins. Clinics. 2006;61(1): 71-76.
8. Young JD. The heart and circulation in severe sepsis. Br J Anaesth. 2004;93:114-120.
9. Hollenberg SM, Cinel I. Bench-to-bedside review: nitric oxide in critical illness-update 2008. Crit Care. 2009;13:218.
10. Kotsovolis G, Kallaras K. The role of endothelium and endogenous vasoactive substances in sepsis. Hippokratia. 2010;14:88-93.
11. Matsuda N, Hattori Y. Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. Smooth Muscle Res. 2007;43:117-137.
12. Murray PT, Wylam ME, Umans JG. Nitric oxide and septic vascular dysfunction. Anesth Analg. 2000;90:89-89.
13. Shah NH, Billiar TR. Role of nitric oxide in inflammation and tissue injury during endotoxemia and hemorrhagic shock. Environ Health Perspect. 1998;106:1139-1143.
14. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.
15. De Backer D, Ortiz JA, Salgado D. Coupling microcirculation to systemic hemodynamics. Curr Opin Crit Care. 2010;16:250-254.
16. Farmer MR, Roberts RE, Gardiner SM, Ralevic V. Effects of in vivo lipopolysaccharide infusion on vasoconstrictor function of rat isolated mesentery, kidney, and aorta. J Pharmacol Exp Ther. 2003; 306:538-545.
17. Silva E, Passos RDH, Ferri MB, Poli de Figueiredo LF. Sepsis: from bench to bedside. Clinics. 2008;63:109-120.
18. Tyagi A, Sethi AK, Girotra G, Mohta M. The microcirculation in sepsis. Ind J Anaesth. 2009;53:281-293.
19. Trzeciak S, Cinel I, Phillip Dellinger R, et al; Microcirculatory Alterations in Resuscitation and Shock (MARS) Investigators. Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med. 2008;15:399-413.
20. De Backer D, Hollenberg S, Boerma C, et al. How to evaluate the microcirculation: report of a round table conference. Crit Care. 2007; 11:R101.
21. Dyson A, Stidwill R, Taylor V, Singer M. Tissue oxygen monitoring in rodent models of shock. Am J Physiol Heart Circ Physiol. 2007;293: 526-533.
22. Elbers PW, Ince C. Mechanisms of critical illness - classifying microcirculatory flow abnormalities in distributive shock. Crit Care. 2006;10:221.
23. Evora PR, Ribeiro PJ, Vincente WV, et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev Bras Cir Cardiovasc. 2009; 24:279-288.
24. Shanmugam G. Vasoplegic syndrome - the role of methylene blue. Eur J Cardiothorac Surg. 2005;28:705-710.
25. Buckley J, Singer M, Clapp L. Role of KATP channels in sepsis. Cardiovasc Res. 2006;72:220-230.
26. Standen NB, Quayle JM, Davies NW, Braiden JE, Huang Y, Nelson MT. Hyperpolarizing vasodilators activate ATP-sensitive K channels in arterial smooth muscle. Science. 1989;245:177-180.
27. D'Emmanuele di Villa Bianca R, Lippolis L, Autore G, et al. Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity. Br J Pharmacol. 2003;140:91-96.
28. Japiassu AM, Salluh JI, Bozza PT, Bozza FA, Castro-Faria-Neto HC. Revisiting steroid treatment for septic shock: molecular actions and clinical effects - a review. Mem Inst Oswaldo Cruz. 2009; 104: 531-548.
29. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008;36:1394-1396.
30. Warrillow S, Egi M, Bellomo R. Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med. 2006;34: 980-985.
31. ATP channel imparts fatal susceptibility to endotoxemia. FASEB J. 2006;20:2271-2280.
32. Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr. 2004; 24:539-577.
33. 2S) - the third gas of interest for pharmacologists. Pharmacol Rep. 2007;59:4-24.
34. Wagner F, Asfar P, Calzia E, Radermacher P, Szabo P. Bench-to-bedside review: hydrogen sulfide - the third gaseous transmitter: applications for critical care. Crit Care. 2009;13(3):213.
35. Doeller JE, Isbell TS, Benavides G, Koenitzer J, Patel H, Patel RP, Lancaster JR Jr. Polarographic measurement of hydrogen sulfide production and consumption by mammalian tissues. Anal Biochem. 2005; 341:40-51.
36. 2S as a novel endogenous gaseous KATP channel opener. EMBO J. 2001; 20:6008-6016.
37. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun. 1997;237:527-531.
38. 2S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol. 2002; 283:474-480.
39. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917-935.
40. Ali MY, Ping CY, Mok YY, et al. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol. 2006;149:625-634.
41. Webb GD, Lim LH, Oh VM, et al. Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. J Pharmacol Exp Ther. 2008;324:876-882.
42. Murphy ME, Brayden JE. Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol. 1995;486: 47-58.
43. Mok YY, Atan MS, Yoke Ping C, et al. Role of hydrogen sulphide in hemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. Br J Pharmacol. 2004;143:881-889.
44. Hui Y, Du J, Tang C, Bin G, Jiang H. Changes in arterial hydrogen sulfide content during septic shock and endotoxic shock in rats. J Infect. 2003;47:155-160.
45. Li L, Bhatia M, Zhu YZ, et al. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J. 2005;19:1196-1198.
46. Zhang H, Zhi L, Moore PK, Bhatia M. Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. Am J Physiol Lung Cell Mol Physiol. 2006;290:1193-1201.
47. Collin M, Anuar FB, Murch O, Bhatia M, Moore PK, Thiemermann C. Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br J Pharmacol. 2005;146:498-505.
48. Holmes CL, Landry DW, Grandon J. Science review: vasopressin and the cardiovascular system part 1 - receptor physiology. Crit Care. 2003; 7:427-434.
49. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120: 989-1002.
50. Holmes CL, Landry DW, Grandon J. Science review: vasopressin and the cardiovascular system part 2 - clinical physiology. Crit Care. 2004; 8:15-23.
51. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358: 877-887.
52. Russell JA, Walley KR, Gordon AC, Cooper J, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med. 2009;37:811-818.
53. Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med. 2009;169:15-24.
54. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2004;29:1696-1702.
55. Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med. 2006;34:2140-2144.
56. Munford RS, Tracey KJ. Is severe sepsis a neuroendocrine disease? Mol Med. 2002;8:437-442.
57. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776-787.